BMO Capital analyst Evan Seigerman raised the firm’s price target on Terns Pharmaceuticals (TERN) to $22 from $15 and keeps an Outperform rating on the shares. The firm increased its probability of success for TERN-701 to 70% and peak unadjusted sales estimate to $3.7B following today’s abstract data. Terns shares may be undervalued with products like Novartis’s Scemblix estimated to reach well over $3B in peak sales, the analyst tells investors in a research note. BMO sees additional upside in the stock even after Monday’s 80% rally.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals price target raised to $35 from $28 at Jefferies
- Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue
- William Blair upgrades Terns Pharmaceuticals after ‘impressive’ data
- Terns Pharmaceuticals upgraded to Outperform from Market Perform at William Blair